How Template Format Flexibility in AI Protein Production Platforms Reshapes Cost Modeling for Reproducibility-Conscious Labs

Template format is the single decision that determines where a CFPS lab's money goes, how often its reactions fail for unexplained reasons, and how fast it can move through a design cycle. A lab that treats linear DNA versus plasmid DNA as a workflow preference is skipping the one choice that actually sets its cost structure, and this piece lays out why, with the specific mechanisms behind it.

The Pivotal Cost Variable in CFPS: Template Format

Switching a CFPS workflow from plasmid to linear DNA eliminates a whole set of steps: no cloning into a vector, no bacterial transformation, no colony picking, no plasmid miniprep, no sequence verification before the construct is usable. Every CFPS reaction runs on three inputs, a DNA template, a cell lysate, and a mix of biochemical components, and of those three, the template is the only one the lab fully controls before the reaction even starts. That makes it the highest-leverage decision in the entire workflow, not a minor procedural choice buried in the methods section. Linear expression templates (LETs), produced directly by PCR, skip the cloning and propagation layer that plasmid work requires, making the resulting savings in time and labor structural. Plasmid construction and propagation can take weeks; LETs can be ready in days, because the molecular cloning steps that plasmids require simply aren't part of the process. Treating that front-end cost as sunk, as something that happened before the "real" experiment began, is how labs end up with cost models that don't match their actual spending.

How Templates Accumulate Cost Across the Lab Workflow

Plasmid and linear DNA route cost through different parts of the lab entirely, and a cost model built around one will misjudge the other. Plasmid cost builds up before a single expression reaction ever runs: molecular biology labor, cloning reagents, bacterial culture, miniprep kits, and sequencing fees, all incurred regardless of how simple the target protein turns out to be. Linear DNA shifts that cost downstream into the reaction itself, into PCR reagents, primer synthesis, and the standard biochemical components of the CFPS mix, while the upstream cloning layer mostly disappears. LETs made through a two-step PCR method skip the cloning steps that plasmid construction needs, and they support parallel translation of large numbers of genes at once, so the throughput advantage compounds the cost advantage as the number of targets grows. Plasmid templates often produce higher CFPS yields than linear templates on a per-reaction basis, so the comparison isn't simply "linear wins. The energy-supply components inside the reaction, including the regeneration system that keeps it running, are the dominant cost driver of the reaction itself, and that cost doesn't move with template format. Template choice can't touch it, but it can eliminate the upstream layer stacked on top of it. A lab running one protein a year absorbs the plasmid overhead easily, since it amortizes over a single project. A lab iterating across dozens or hundreds of variants per design cycle pays that overhead repeatedly. A cost model that ignores iteration frequency and looks only at per-reaction reagent spend will miss where the money actually goes.

Linear DNA's reproducibility burden and its cost

Linear DNA's speed and cost advantages carry a real liability: nuclease-mediated degradation and PCR-to-PCR variability. Linear templates lack the circular protection a plasmid backbone provides, so they're more exposed to nuclease activity in lysate-based reactions, and batch-to-batch differences in PCR output introduce variability that a naive reagent-price comparison won't catch. Labs address this in several ways, including chemical modification of the template ends, genomic changes to the expression host to reduce nuclease activity, addition of nuclease inhibitors, or use of DNA-binding proteins to shield the template, and each of these options adds either reagent cost or protocol complexity. When a lab builds its own LETs in-house, it is, in effect, running a small reagent manufacturing operation without the validation infrastructure that a commercial reagent supplier maintains. The labor spent validating that process is real money, even though it almost never appears as its own line in a reagent budget. Reproducibility problems don't stop at the template. A typical CFPS reaction depends on roughly 35 to 38 additional components, and variation in how any of those are prepared compounds template-level variability. An honest cost model has to include the template stabilization strategy you chose, the quality control run on every PCR product before it goes into a reaction, and the labor spent troubleshooting when linear-template reactions underperform. None of that is visible if the comparison stops at reagent catalog prices.

How reagent system design shapes template-flexibility reproducibility risk

The reproducibility burden tied to linear DNA isn't fixed by the format itself. It depends on how well-characterized, documented, and lot-controlled the surrounding reagent system is, which makes the platform decision just as consequential as the template decision. A CFPS reaction is a system of components that interact with each other, so variability in any single part propagates through the rest. A lysate with documented lot-level quality control narrows the space of unexplained variation, and once that's done, template variability becomes the one remaining unknown among several previously tangled together. One yeast CFPS system showed low variability between different lysate lots, and even lower variability between replicate runs using the same lot on different days, which shows that lysate standardization is both achievable and something that can be measured directly, not just assumed. Lot-level QC data is what makes that possible in practice: a lab that can check its current lysate lot against a documented reference turns troubleshooting into a process of elimination. The data tells the lab whether the template is the problem or something else is. Formulation transparency matters for the same reason, because a reagent system with a documented composition lets a lab reason about why a linear template behaves one way in one context and differently in another, while a closed kit hands back a yield number and nothing to explain it. The OpenCFPS E. coli Core Kit (Z0001) from Sepia Biosciences reflects this principle directly: its formulations are documented, lot-level QC data is published, and the system works with both linear DNA and plasmid DNA, so switching template format doesn't force a lab to switch platforms. The transparency built into reagent systems like this, where suppliers publish formulations and lot-level QC data, turns the cost-accumulation mechanism described above into something a lab can actually model and quantify.

How iteration speed scales template-level cost in variant-screening workflows

If you run machine-learning-directed protein engineering or large variant panels, the template decision doesn't scale in a straight line. The plasmid overhead grows as a share of total program cost as the variant count climbs. If your design cycle covers a few dozen variants, the per-variant plasmid overhead is manageable. Across hundreds or thousands of variants, that same upstream labor and reagent cost either eats the budget or imposes a throughput ceiling that forces the lab to test fewer variants than the science actually calls for. Thornton and colleagues, writing in ACS Synthetic Biology in May 2025, used CFPS to screen 138 machine-learning-generated protein variants in 384-well format, producing and screening each collection in six hours total, in the same plate, and came away with several active variants and a 4-fold improvement in the fitness of the test protease. That pace simply isn't compatible with plasmid-based template prep running at the same speed. The POSTECH i-POPFLEX platform, described by Chae and colleagues in Trends in Biotechnology (published online June 6, 2026), paired automation with modular component design, and that cut preparation costs sharply and brought prep time down from four days to two compared with commercially available kits. Its modular structure lets components be added or removed per experiment, a feature that only matters if the template layer is already flexible enough to keep up with rapid variant cycling. Separately, an OpenAI/GPT-5 autonomous lab effort tested more than 36,000 unique CFPS reaction compositions across hundreds of automated plates, a scale at which reagent cost per reaction becomes the binding constraint, but only because templates could be supplied as fast as the automation consumed them, something only linear DNA makes possible. The right unit for a cost model here is the per-variant cost across a full design-build-test-learn cycle, counting upstream prep, reaction reagents, and the rework that follows failed cycles. That's the only number that lets the two formats be compared honestly.

Recent advances in reagent formulation optimization and the remaining cost ceiling

The underlying chemistry no longer fixes the cost ceiling in CFPS. A team reporting in Nature Communications used a definitive screening design to search more than a thousand reagent formulations and landed on a simple, reproducible 12-component system, targeting a reagent cost below $100 per gram of protein, closer to what cell-based production costs. At 4-mL scale with oxygen supplementation, that optimized formulation reached a protein yield of 3.7 ± 0.2 g/L at roughly $39 per gram. That search was only possible because the team could cycle through large numbers of reaction compositions quickly, a workflow that depends on linear DNA's ability to supply fresh template for each condition without waiting on a cloning step. The GPT-5 autonomous lab work from February 2026 achieved a meaningful drop in protein production cost and a real gain in reagent cost efficiency across six closed-loop experimental rounds, running thousands of reactions per round, again a pace that requires template supply to match automation throughput. These figures are not the current baseline cost of running CFPS generally; they represent what's achievable once formulation is optimized through systematic, high-throughput search, a search method itself built on template flexibility. The practical takeaway for cost modeling is that published cost floors for CFPS keep moving, and a lab locked into plasmid-only templates won't be positioned to adopt these optimized formulations as they emerge, because the formulations were designed and validated at scales plasmid prep can't reach.

Building an accurate cost model: the variables a template-format-aware framework must include

A cost model built only on reagent price misses at least five categories, and template format changes the size of every one. The first is upstream template preparation. For plasmid, that means cloning labor, transformation, colony selection, sequence verification, and miniprep reagents, multiplied by however many variants run in a design cycle. For linear DNA, that collapses down to PCR reagents and primer synthesis, with the cost of template quality control and any stabilization strategy, such as end modification, added back in. The second category is per-reaction reagent cost, where the energy regeneration system, lysate, and biochemical components dominate, and these don't vary by format. The energy system needed for protein production drives most of the cost inside the reaction, so a standardized, high-performance reagent formulation becomes the fixed reference point you judge template decisions against. Reagent transparency and reproducible kit performance matter for getting the model right. A higher-yield formulation lowers the cost per milligram of protein even when the per-reaction reagent spend looks similar on paper. The third category is reproducibility assurance: the labor and reagents spent on lot-level QC, repeat runs to confirm variant rankings, and troubleshooting failed reactions. That cost drops when the reagent system is well-characterized with lot data on hand, and rises when the system is opaque or the lab is mixing its own components with no validated reference to check against. The fourth category is iteration cycle time. The weeks that plasmid cloning takes represent delayed decisions in a design-build-test-learn loop, and in ML-directed engineering work, delayed decisions mean slower model convergence and more cycles needed to hit a fitness target, so a model that ignores cycle time will undercount linear DNA's speed advantage. The fifth category is platform compatibility and switching cost. A lab built around one template format can face real switching costs if its platform or reagent system changes later, and compatibility with both linear and plasmid DNA, as with OpenCFPS from Sepia Biosciences, which is documented for linear DNA, plasmid DNA, and low DNA working concentrations, cuts that option cost and keeps the lab from getting locked into one mode. If you run through all five categories, you get a per-variant program cost across a full design cycle, not a per-reaction reagent price.

Platform and reagent choices from a template-format-aware cost model

Once a lab has priced out its workflow using the framework above, its platform requirements stop being generic. They depend on whether its throughput, reproducibility needs, and iteration speed put it in linear-DNA-dominant territory, plasmid-dominant territory, or somewhere that needs both. Labs running high-throughput variant screens, in 96-, 384-, or 1536-well format, ML-directed design cycles, or biofoundry-style design-build-test-learn workflows, should look for platforms built to work with linear DNA from the start rather than as a workaround, and that publish lot-level QC data so the reproducibility assurance cost stays low. Labs producing milligram quantities for characterization or assay development may still find plasmid templates make sense for individual targets, where the prep overhead amortizes well, but they should pick a reagent system that works with both formats so moving from a screen to production doesn't force a platform switch. The OpenCFPS E. coli Core Kit (Z0001) from Sepia Biosciences is built for both modes, screening large numbers of variants fast and scaling up winners to milligram quantities, and it's documented as compatible with linear DNA, plasmid DNA, and low DNA working concentrations, with published formulations, available lot-level QC data, and pricing as low as $25/mL, against kit pricing that can run close to $1,330/mL at comparable performance. That gap puts the reagent economics within reach at exactly the throughputs where linear DNA's structural advantages matter most. The i-POPFLEX result from Chae and colleagues, showing that automation paired with modular component design cuts costs sharply compared with commercial kits, points toward where the field is heading: platforms built for component-level customization and automated reproducibility will outperform closed kits over time, and reagent transparency makes that customization possible. What follows is a short set of criteria any reproducibility-conscious lab can apply directly: documented compatibility with linear DNA at concentrations that hold up at production scale; a published formulation that makes troubleshooting possible instead of guesswork; lot-level QC data with inter-lot variability actually quantified; pricing that doesn't impose a per-variant cost ceiling before the biology does; and compatibility with standard plate formats and liquid-handling automation. Applied honestly, those five criteria are what should drive the platform decision, not the other way around.